Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on March 5, 2018, reporting events occurring on March 2, 2018, and March 5, 2018. The filing addresses a material modification to the rights of security holders regarding previously issued Series A Preferred Stock and warrants.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on capital structure adjustments.
- Series A Preferred Stock: 13,350 shares outstanding (convertible at 200:1 ratio).
- Warrants: 2,070,000 warrants outstanding with an exercise price of $5.50 per share.
- Warrant Cancellation Payment: $0.001 per unexercised share upon cancellation.
Material Changes
The Company satisfied specific conditions triggering forced conversion and warrant cancellation:
- Forced Conversion: The volume-weighted average price of common stock exceeded 300% of the conversion price for 30 consecutive trading days, and average daily trading volume exceeded $500,000. Consequently, all Series A Preferred Stock will convert to common stock effective March 7, 2018.
- Warrant Call: The volume-weighted average price of common stock exceeded 300% of the $5.50 exercise price for 30 consecutive trading days, and average daily trading volume exceeded $500,000. The Company called all outstanding warrants for cancellation.
Outlook, Risks, and Unusual Items
Unusual Items: The forced conversion and warrant call are unusual events driven by significant appreciation in the Company's stock price relative to the original offering terms.
Timeline and Obligations:
- Warrants remaining outstanding after 6:30 p.m. EST on March 19, 2018, will be cancelled.
- The Company will pay holders $0.001 for each unexercised share under the cancelled warrants.
Risks/Contingencies: The filing notes that summaries of the Certificate of Designation and Warrants are subject to the full terms of the original documents filed in April 2017.
Investor Verification Checklist
- Verify the exact number of common shares resulting from the conversion of 13,350 Series A Preferred Stock shares (200:1 ratio).
- Confirm the total cash payout obligation for unexercised warrants ($0.001 per share).
- Review the press release (Exhibit 99.1) for any additional commentary on the stock price performance triggering these events.
- Check subsequent filings to confirm the completion of the conversion and warrant cancellation by the March 19, 2018 deadline.